21895-22-7

Basic information

• Product Name: Phenol, 2-(1-iminoethyl)-
• CAS NO: 21895-22-7
• Molecular Formula: C8H9NO
• Molecular Weight: 135.166
• Mol File: 21895-22-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Phenol, 2-(1-iminoethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 2-(1-iminoethyl)-(21895-22-7)
• EPA Substance Registry System: Phenol, 2-(1-iminoethyl)-(21895-22-7)

Safety Data

• Hazardous Substances Data: 21895-22-7(Hazardous Substances Data)

Upstream product

• 118-93-4 o-hydroxyacetophenone 
• 582-24-1 1-phenyl-2-hydroxyethanone 

Downstream Products

• 1033425-24-9 4-methyl-3-nitro-2-(trifluoromethyl)-2H-chromene 
• 1033425-33-0 (E)-1,1,1-trifluoro-3-nitro-N-[1-(2-hydroxyphenyl)ethylidene]propan-2-amine 
• 1033425-21-6 4-methyl-3-nitro-2-(trichloromethyl)-2H-chromene 
• 1033425-27-2 (E)-1,1,1-trichloro-3-nitro-N-[1-(2-hydroxyphenyl)ethylidene]propan-2-amine 
• 118-93-4 o-hydroxyacetophenone 
• 89985-53-5 1-(2-hydroxyphenyl)ethylamine 
• 133511-37-2 2-[(1S)-1-aminoethyl]phenol 
• 1607023-11-9 3-(benzo[d]isoxazol-3-yl)-5-(4-chloro-3-ethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607023-10-8 3-(benzo[d]isoxazol-3-yl)-5-(3,4-dichlorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607023-00-6 3-(benzo[d]isoxazol-3-yl)-5-(4-chloro-3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 37924-85-9 3-bromomethyl-1,2-benzisoxazole 
• 123983-05-1 2?[(1R)?1-aminoethyl]phenol 
• 1345515-18-5 C₈H₈ClNO 
• 95-21-6 2-methyl-1,3-benzoxazole 

Relevant articles and documents

Asymmetric Transfer Hydrogenation of o-Hydroxyphenyl Ketones: Utilizing Directing Effects That Optimize the Asymmetric Synthesis of Challenging Alcohols

A systematic range of o-hydroxyphenyl ketones were reduced under asymmetric transfer hydrogenation conditions using the C3-tethered catalyst 2. Two directing effects, i.e., an o-hydroxyphenyl coupled to a bulky aromatic on the opposite side of the ketone substrate, combine in a matched manner to deliver reduction products with very high enantiomeric excess.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Synthesis, characterization, and X-ray crystal structures of copper(II) and nickel(II) complexes with Schiff base

New copper(II) complexes, [Cu2L1L2] · ClO4 (I) and [Ni(L3)2] (II), where L1 is the monoanionic form of 2-[1-(2-emthylaminoethylimino)ethyl] phenol, L2 is the dianionic form of N,N′-ethylene-bis(2- hydroxyacetophenonylideneimine), L3 is the mono-anionic form of 2-(1-iminoethyl)phenol, were prepared and characterized using elemental analysis, FT-IR spectroscopy, and X-ray single-crystal diffraction. In complex I, the Cu(1) atom is coordinated by the NNO tridentate ligand L1 and the two phenolate O atoms of L2, forming a square pyramidal geometry. The Cu(2) atom in complex I is coordinated by the NNOO tetradenate ligand L2, forming a square planar geometry. The Ni atom in complex II is coordinated by two phenolate O and two imine N atoms from two ligands L 3, forming a square planar geometry. In the crystal structure of I, the perchlorate anions are linked to the dinuclear copper(II) complex cations through intermolecular N-H.O hydrogen bonds. In the crystal structure of II, the mononuclear nickel complex molecules are linked through intermolecular N-H.O hydrogen bonds, forming a trimer.